Navigation Links
Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Date:4/15/2008

Biosciences, of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We are also investigating RDEA806 for the treatment of gout. Our lead MEK inhibitor, RDEA119, is in Phase 1 studies in advanced cancer patients and healthy volunteers for assessment as a treatment of inflammatory diseases. RDEA436, our second generation MEK inhibitor for the treatment of cancer and inflammatory diseases, has been evaluated in human micro-dose pharmacokinetic studies and selected as a development candidate. In addition to the foregoing clinical programs, we are investigating other drug candidates in earlier stages of preclinical development and discovery.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: sufficiency of cash resources and our goals, including the expected properties and benefits of RDEA806, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... MUMBAI, India , July 11, 2014 /PRNewswire/ ... the treatment of cancer are being highlighted in ... Mumbai from 10-12 July, 2014.  Renowned ... meeting to share best practices and exchange knowledge ... more precise, accurate and efficient. ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
(Date:7/11/2014)... Operators and owners stand ... fuel costs now that model 2019 will ... standards are phasing in 2014-2018 standards. ... to install new features into their vehicles ... , 2.    Efficient driveline components which reduce friction ...
(Date:7/11/2014)... Children who have emergency surgery on weekends are ... death than those who have weekday surgeries, according ... Hopkins researchers noted that the risk of death ... nearly 440,000 simple emergency surgeries that children across ... The surgeries are considered generally safe and ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... comes to the summer concert schedule, it just isn’t complete without ... of the biggest names in country music and one of the ... his “That’s My Kind of Night” tour featuring Lee Brice and ... through the rest of the summer and into the fall includes ...
(Date:7/11/2014)... 2014 Alliance for Cancer Gene ... dedicated exclusively to cell and gene therapies for ... joined the organization as Senior Development Officer. , ... experience securing gifts and addressing influential donors. Prior ... Director for NewYork Presbyterian Hospital/Columbia University Medical Center, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4
... the first time in Florida, patients with glaucoma have a ... invasive procedure, which is available at Mayo Clinic and takes ... eye and stabilize the vision. , "The goal of ... says ophthalmologist Rajesh Shetty, M.D. He says that some ...
... The StrionAir System A130,air purification product is ... "It provides HVAC efficiency to the third power," ... First, it achieves LEED-qualifying MERV* 13 efficiency ... That,s half the pressure drop of the,newest "green" ...
... video communicates the importance of skin cancer self-examination, ... Partnership for,Skin Health, a public service initiative that ... and explore solutions for,skin health, has tapped actress ... about self-examination for skin cancer detection. As the ...
... and "The Celebrity Apprentice" finalist Trace Adkins will serve,as ... Food Allergy: Moving,Toward A Cure., The event, to ... well as,online, is sponsored by the Food Allergy & ... education and research., Adkins, a multifaceted entertainer who ...
... Technologies,Inc., an innovator of endovascular treatments for peripheral ... patent for its,Pathway PV(TM) Atherectomy System. The issuance ... to Pathway Medical,s innovative,atherectomy system, which is designed ... legs. Pathway Medical has a total of three ...
... Workout and Recovery Drinks Developed by UT,s Dr. John Ivy in Consultation,with Eddie ... ... Coach, AUSTIN, Texas, June 25 When ... Omaha at,the U.S. Olympic Team Trials for Swimming to cheer on former University ...
Cached Medicine News:Health News:Glaucoma procedure now available at Mayo Clinic aims to prevent further eye damage 2Health News:StrionAir System A130 Air Purification Product Reduces Fan Energy by More Than 10 Percent 2Health News:Neutrogena(R) Partnership For Skin Health Taps Malin Akerman to Educate About Skin Cancer Detection 2Health News:Neutrogena(R) Partnership For Skin Health Taps Malin Akerman to Educate About Skin Cancer Detection 3Health News:Country Music Star Trace Adkins to Be Honorary Chair of Nationwide Walk for Food Allergy 2Health News:Country Music Star Trace Adkins to Be Honorary Chair of Nationwide Walk for Food Allergy 3Health News:Austin Company Makes a Splash at U.S. Olympic Team Swimming Trials 2Health News:Austin Company Makes a Splash at U.S. Olympic Team Swimming Trials 3Health News:Austin Company Makes a Splash at U.S. Olympic Team Swimming Trials 4Health News:Austin Company Makes a Splash at U.S. Olympic Team Swimming Trials 5
... Accutest H. pylori WB test ... the qualitative detection of lgG ... in human whole blood. This ... an aid in the diagnosis ...
... OraQuick is an FDA approved ... whole blood test used to ... HIV-1 infection. This CLIA waived ... of antibodies to HIV-1, requires ...
... is designed to detect the IgM ... whole blood. The QuickVue+ Infectious Mononucleosis ... erythrocytes which give a greater sensitivity ... from sheep and horse erythrocytes. QuickVue+ ...
... point-of-care diagnostic test that can reliably and ... and B. The test uses a unique ... assists viral replication by promoting the release ... ZstatFlu substrate is labeled with a chromagen. ...
Medicine Products: